AMG 193
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
MTAP-deleted NSCLC
Conditions
MTAP-deleted NSCLC
Trial Timeline
Dec 26, 2024 → Nov 29, 2030
NCT ID
NCT06593522About AMG 193
AMG 193 is a phase 2 stage product being developed by Amgen for MTAP-deleted NSCLC. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06593522. Target conditions include MTAP-deleted NSCLC.
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06593522 | Phase 2 | Recruiting |
Competing Products
3 competing products in MTAP-deleted NSCLC
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| BAY 3713372 | Bayer | Phase 1/2 | 36 |
| BG-89894 | BeOne Medicines | Phase 1 | 33 |
| S095035 + TNG462 | Tango Therapeutics | Phase 1/2 | 33 |